Blog Archive

Spotlight On – Q1 2024

RECENT FACET SUCCESSES – JUST A FEW HIGHLIGHTS FACET HELPS SMALL ORGANIZATION HOLD SUCCESSFUL FDA MEETING Small organization reaches FDA agreement on BLA requirements for novel diagnostic in Type C meeting.  Facet often w...

Read More
Spotlight

New Services: Strategic Statistical Support

Facet’s new Strategic Statistical Services group uses statistical principles and methodologies to maximize precision and efficiency in the development of drugs, biologics, medical devices, and combination products.  More and mo...

Read More

Facet By The Numbers – Q4 2023

FACET BY THE NUMBERS Early-stage development highlights:  3 IND preparation and submissions for NCEs, 3 IND clearances; over 35 IND amendments (e.g., new protocols/amendments, CMC updates, nonclinical study reports, annual repo...

Read More

FDA Round Up – Q4 2023

FDA ROUNDUP: New FDA guidance: Stimulant Use Disorders:  Developing Drugs for Treatment (Draft October 2023) – The purpose of this guidance is to provide Sponsors with recommendations on clinical development of drugs for ...

Read More

Did You Know – Q4 2023

DID YOU KNOW? Facet’s strategic and tactical regulatory affairs, statistics, regulatory writing, and commercialization experts lead small organizations to faster and more efficient product development, US registration, and com...

Read More

Spotlight On – Q4 2023

RECENT FACET SUCCESSES – JUST A FEW HIGHLIGHTS  FACET HELPS PHYSICIAN GET IND FULL HOLD LIFTED Facet successfully prepares Complete Response (CR) to Investigator IND full hold to allow PI to proceed into the clinic.  FDA ...

Read More
Go to Top